<DOC>
	<DOCNO>NCT00903396</DOCNO>
	<brief_summary>RATIONALE : Palonosetron hydrochloride may prevent nausea vomit cause radiation therapy . It yet know whether palonosetron hydrochloride effective placebo prevent nausea vomit . PURPOSE : This randomized phase II trial study side effect palonosetron hydrochloride see well work prevent nausea vomit cause radiation therapy patient primary abdominal cancer .</brief_summary>
	<brief_title>Palonosetron Hydrochloride Preventing Nausea Vomiting Caused Radiation Therapy Patients With Primary Abdominal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate rate complete response , define vomit nausea , patient primary gastrointestinal and/or retroperitoneal sarcomas treat two different dose schedule palonosetron hydrochloride abdominal radiotherapy part cancer treatment . - Determine tolerability palonosetron hydrochloride v placebo patient . - Validate patient diary assess nausea vomit compare alternative method measure nausea vomit order determine optimal approach future study . OUTLINE : Patients stratify accord plan radiotherapy duration ( &lt; 5 week vs ≥ 5 week ) , plan concurrent fluorouracil ( yes v ) , gender . Patients randomize 1 4 treatment arm . - Arm I : Patients receive palonosetron hydrochloride IV day 1 . - Arm II : Patients receive palonosetron hydrochloride IV day 1 4 . - Arm III : Patients receive placebo IV day 1 . - Arm IV : Patients receive placebo IV day 1 4 . In arm , course repeat weekly radiotherapy absence disease progression unacceptable toxicity . Patients complete nausea vomit questionnaire diary baseline daily radiotherapy . Patients also complete symptom experience diary weekly radiotherapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Appendiceal Neoplasms</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary gastrointestinal and/or retroperitoneal sarcoma Scheduled undergo ≥ 3000 cGy ≥ 3 week external beam radiation abdomen Radiotherapy field extend T11 L3 , size ≥ 100 cm^2 No brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Negative pregnancy test Not pregnant nursing Fertile patient must use effective contraception Able complete questionnaire ( ) alone assistance Willing return NCCTG enrol institution followup Able reliably take oral medication ( purpose rescue medication ) No hypersensitivity palonosetron hydrochloride selective 5HT3 receptor antagonists No comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate study entry interfere significantly proper assessment safety toxicity prescribe regimens No nausea ≤ 48 hour prior study enrollment No history dystonic reaction prochlorperazine haloperidol related agent PRIOR CONCURRENT THERAPY : See Disease Characteristics More 7 day since prior agent know significant effect emesis , include follow : Ondansetron Sedating antihistamine Antipsychotics Cannabinoids Corticosteroids Metoclopramide Narcotic analgesic Benzodiazepines More 7 day since prior chemotherapy fluorouracil capecitabine use radiosensitizer More 7 day since prior cetuximab More 7 day since prior concurrent oral steroid No prior palonosetron hydrochloride</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>nausea vomit</keyword>
	<keyword>gastrointestinal carcinoid tumor</keyword>
	<keyword>anal cancer</keyword>
	<keyword>carcinoma appendix</keyword>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>extrahepatic bile duct cancer</keyword>
	<keyword>gallbladder cancer</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>liver intrahepatic biliary tract cancer</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>small intestine cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>